As of July 31, 2025, NeuroThera Labs Inc. has 18.10M shares outstanding.
| Shares Outstanding | 18.10M |
As of July 31, 2025, NeuroThera Labs Inc. maintains a current ratio of 6.70, meaning it holds 6.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 6.70 |
| Quick Ratio | 6.70 |
Over the twelve months ended July 31, 2025, NeuroThera Labs Inc. posted a negative return on equity (ROE) of -22.64, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -20.32, reflecting losses generated across the asset base.
| Return on Equity (ROE) | -22.64 |
| Return on Assets (ROA) | -20.32 |
As of the close on October 22, 2026, NeuroThera Labs Inc.'s stock has declined approximately 23.33% over the past 52 weeks.
| 52-Week Price Change | -23.33% |
| 50-Day Moving Average | 3.37 |
Over the twelve months ended July 31, 2025, NeuroThera Labs Inc. generated - - in revenue and converted that into -189,228.51 in net income, yielding earnings per share of -0.02. EBITDA reached -189,124.01, while operating income came in at -189,124.01.
| Operating Income | -189,124.01 |
| Pretax Income | -189,228.51 |
| Net Income | -189,228.51 |
| EBITDA | -189,124.01 |
| EBIT | -189,124.01 |
| Earnings Per Share (EPS) | -0.02 |
These figures are as of July 31, 2025. Total book value stands at 893,365.22, with working capital of 893,365.22 providing operational flexibility.
| Cash & Cash Equivalents | 1.05M |
| Net Debt | -1.05M |
| Equity (Book Value) | 893,365.22 |
| Book Value Per Share | 0.05 |
| Working Capital | 893,365.22 |
NeuroThera Labs Inc. produced -58,516.72 in operating cash flow over the twelve months ended July 31, 2025.
| Operating Cash Flow | -58,516.72 |
| Free Cash Flow | -58,516.72 |
| FCF Per Share | -0.01 |
NeuroThera Labs Inc.'s most recent stock split took place on September 2, 2026 with a 14:1 split ratio.
| Last Split Date | 9/2/2026 |
| Split Ratio | 14:1 |
Already premium?